CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS
· Delayed Price · Currency is USD
0.0100
0.00 (0.00%)
Jan 17, 2025, 4:00 PM EST
CNBX Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '24 Nov 30, 2024 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | Aug '20 Aug 31, 2020 | 2019 - 2015 |
| Revenue | 0.04 | 0.13 | 0.41 | 0.03 | - | 0.01 | Upgrade
|
| Revenue Growth (YoY) | -91.87% | -68.29% | 1269.13% | - | - | -27.29% | Upgrade
|
| Gross Profit | 0.04 | 0.13 | 0.41 | 0.03 | - | 0.01 | Upgrade
|
| Selling, General & Admin | 0.41 | 0.52 | 0.91 | 1.8 | 0.83 | 1.37 | Upgrade
|
| Research & Development | 0.08 | 0.19 | 0.43 | 1.18 | 1.77 | 1.68 | Upgrade
|
| Operating Expenses | 0.49 | 0.71 | 1.34 | 2.98 | 2.6 | 3.05 | Upgrade
|
| Operating Income | -0.45 | -0.58 | -0.93 | -2.95 | -2.6 | -3.04 | Upgrade
|
| Interest Expense | -0.01 | -0.02 | -0 | -0 | -0 | -0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | 0 | -0.06 | -0.02 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0.05 | -0.72 | -0.96 | -4.42 | Upgrade
|
| EBT Excluding Unusual Items | -0.46 | -0.61 | -0.98 | -3.74 | -3.59 | -7.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.2 | 0.07 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.09 | -0.09 | -2.73 | 0.01 | 0.2 | - | Upgrade
|
| Pretax Income | -0.55 | -0.7 | -3.71 | -3.72 | -3.19 | -7.47 | Upgrade
|
| Earnings From Continuing Operations | -0.55 | -0.7 | -3.71 | -3.72 | -3.19 | -7.47 | Upgrade
|
| Net Income | -0.55 | -0.7 | -3.71 | -3.72 | -3.19 | -7.47 | Upgrade
|
| Net Income to Common | -0.55 | -0.7 | -3.71 | -3.72 | -3.19 | -7.47 | Upgrade
|
| Shares Outstanding (Basic) | 31 | 30 | 9 | 1 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 30 | 9 | 1 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 101.19% | 242.76% | 621.77% | 5.92% | 2.95% | 1.59% | Upgrade
|
| EPS (Basic) | -0.02 | -0.02 | -0.42 | -3.05 | -2.77 | -6.66 | Upgrade
|
| EPS (Diluted) | -0.02 | -0.02 | -0.42 | -3.05 | -2.77 | -6.66 | Upgrade
|
| Free Cash Flow | -0.21 | -0.25 | -0.11 | -1.68 | -2.49 | -2.85 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.01 | -1.37 | -2.16 | -2.54 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | -1102.63% | -448.31% | -227.07% | -9860.37% | - | -42524.13% | Upgrade
|
| Profit Margin | -1355.97% | -534.46% | -904.57% | -12428.23% | - | -104337.91% | Upgrade
|
| Free Cash Flow Margin | -520.46% | -188.71% | -27.43% | -5610.68% | - | -39830.98% | Upgrade
|
| EBITDA | -0.4 | -0.51 | -0.77 | -2.76 | -2.38 | -2.83 | Upgrade
|
| EBITDA Margin | - | - | -187.56% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.05 | 0.07 | 0.16 | 0.2 | 0.22 | 0.22 | Upgrade
|
| EBIT | -0.45 | -0.58 | -0.93 | -2.95 | -2.6 | -3.04 | Upgrade
|
| EBIT Margin | - | - | -227.07% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.